|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||3.6300 - 3.8000|
|52 Week Range||2.0700 - 8.4190|
|Beta (3Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of PF708 for the treatment of osteoporosis. The application is submitted as a 505(b)(2) NDA and references Eli Lilly and Company’s Forteo® (teriparatide) as the Reference Listed Drug.
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018 SAN DIEGO, Nov. 07, 2018 -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and.
SAN DIEGO, Oct. 25, 2018 -- Pfenex Inc. (NYSE AMERICAN: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression.
Pfenex Inc. (NYSE American: PFNX) (“Pfenex” or the “Company”), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today reported, as required by the NYSE American Company Guide, an equity inducement award to Shawn Scranton, the Company’s new Sr. Vice President, Chief Operating Officer, who officially commenced employment with the Company on October 1, 2018. The stock option was granted to Mr. Scranton pursuant to the Pfenex Inc. 2016 Inducement Equity Incentive Plan, which was approved by the Company’s board of directors under Rule 711(a) and the other relevant rules of the NYSE American Company Guide for equity grants to induce new employees to enter into employment with the Company.
SAN DIEGO, Sept. 21, 2018-- Pfenex Inc. announced today that it will be presenting at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York.. President and Chief Executive Officer, Eef Schimmelpennink, ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Pfenex, Inc. (NYSE American: PFNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. ...
- PF708-301 findings show comparable overall profiles of PF708 and Forteo® - No imbalances in severity or incidence of adverse events - Company is on track for submission of NDA in third quarter 2018 - ...
SAN DIEGO , May 10, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology ® to ...
SAN DIEGO , April 30, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its first quarter 2018 financial results will be released on Thursday, May 10, 2018 , after the market ...